kabutan

CanBas Co.,Ltd.(4575) Summary

4575
TSE Growth
CanBas Co.,Ltd.
1,000
JPY
+2
(+0.20%)
Jul 28, 11:30 am JST
6.76
USD
Jul 27, 10:30 pm EDT
Result
PTS
outside of trading hours
1,000.1
Jul 28, 11:15 am JST
Summary Chart Historical News Financial Result
PER
PBR
7.48
Yield
ー%
Margin Trading Ratio
Stock Price
Jul 28, 2025
Opening Jul 28, 9:00 am
1,005 JPY 6.80 USD
Previous Close Jul 25
998 JPY 6.79 USD
High Jul 28, 9:24 am
1,009 JPY 6.83 USD
Low Jul 28, 9:09 am
995 JPY 6.73 USD
Volume
69,100
Trading Value
0.07B JPY 0.47M USD
VWAP
1001.6 JPY 6.78 USD
Minimum Trading Value
100,000 JPY 676 USD
Market Cap
0.02T JPY 0.13B USD
Number of Trades
182
Liquidity & Number of Trades
As of Jul 28, 2025
Liquidity
High
1-Year Average
1,917
1-Year High Sep 18, 2024
27,787
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jul 18, 2025 0 1,881,300
Jul 11, 2025 0 1,903,000
Jul 4, 2025 0 1,922,900
Jun 27, 2025 0 1,890,400
Jun 20, 2025 0 1,949,300
Company Profile
CanBas Co., Ltd. is a drug discovery venture specializing in anticancer drug development. Its primary source of income is research and development support funds. The company is actively seeking partnership opportunities.
Sector
Pharmaceuticals
CanBas Co., Ltd. is a drug discovery venture focusing on basic research, early clinical development, and late-stage clinical development of anticancer drugs. Leveraging its unique drug discovery approach, the company has a development pipeline consisting of multiple drug candidate compounds. CanBas utilizes external specialized institutions and a scientific advisory board, aiming for synergy by combining in-house development with strategic partnerships with pharmaceutical companies. The company's lead compound, CBP501, is currently undergoing Phase 2 clinical trials in combination with immune checkpoint inhibitor antibodies. CBS9106 has been licensed to a U.S. company and is progressing through clinical development. In addition to these, CanBas is conducting exploratory research on multiple novel candidate compounds. The company's immediate priorities are accelerating the development of CBP501 and maximizing its chances of success, while continuing basic research to deepen understanding of existing pipelines and generate next-generation pipelines. Continuous fundraising through direct financing is also positioned as one of the company's challenges and strategies to support these efforts.